Synthaverse (SVE) Stock Overview
A pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
SVE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Synthaverse S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł3.07 |
| 52 Week High | zł5.91 |
| 52 Week Low | zł3.00 |
| Beta | 0 |
| 1 Month Change | -17.47% |
| 3 Month Change | -17.58% |
| 1 Year Change | -46.14% |
| 3 Year Change | -47.70% |
| 5 Year Change | -68.36% |
| Change since IPO | -36.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| SVE | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -2.8% | 2.8% | 0.5% |
| 1Y | -46.1% | -9.5% | 23.9% |
Return vs Industry: SVE underperformed the Polish Biotechs industry which returned -9.5% over the past year.
Return vs Market: SVE underperformed the Polish Market which returned 23.9% over the past year.
Price Volatility
| SVE volatility | |
|---|---|
| SVE Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 5.6% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 10.7% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: SVE has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: SVE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | n/a | Artur Chodkowski | synthaverse.com |
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 50 and GAMMA anty-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines.
Synthaverse S.A. Fundamentals Summary
| SVE fundamental statistics | |
|---|---|
| Market cap | zł220.10m |
| Earnings (TTM) | -zł19.93m |
| Revenue (TTM) | zł42.01m |
Is SVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SVE income statement (TTM) | |
|---|---|
| Revenue | zł42.01m |
| Cost of Revenue | zł18.45m |
| Gross Profit | zł23.56m |
| Other Expenses | zł43.50m |
| Earnings | -zł19.93m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 28, 2026
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 56.09% |
| Net Profit Margin | -47.45% |
| Debt/Equity Ratio | 64.0% |
How did SVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/19 21:50 |
| End of Day Share Price | 2026/05/19 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Synthaverse S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.